Idarubicin plus cytarabine as first-line treatment of acute nonlymphoblastic leukemia.
Lambertenghi-Deliliers
G
G
Instituto di Scienze Mediche, University of Milan, Italy.
Annaloro
C
C
Cortelezzi
A
A
Cortellaro
M
M
Della Volpe
A
A
Maiolo
A T
AT
Mozzana
R
R
Pogliani
E
E
Pozzoli
E
E
Polli
E E
EE
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D003561:Cytarabine; D015255:Idarubicin